aibioNRx Pharmaceuticals says $8.8 million raise had no warrants or repricing terms
Tickers NRXP
The $8.8 million combines an August registered direct offering with at-the-market sales since July 1, 2025. The company says none of it carried warrants, repricing or variable-rate terms, but the filing gives no share count, price or investor names.
Key facts
- Company
- NRX Pharmaceuticals, Inc. (NASDAQ: NRXP)
- News type
- Financings
- Primary source
- NRX Pharmaceuticals, Inc. 8-K (2025-09-08)
What the company clarified
NRx Pharmaceuticals, Inc. filed a Form 8-K with the Securities and Exchange Commission on September 8, 2025 to clarify how it reached the roughly $8.8 million it cited in a September 2, 2025 press release. The report is signed by Jonathan Javitt, the company's interim chief executive officer.
The company says the total has two parts. The first is gross proceeds from a registered direct common stock offering announced in August 2025. The second is sales under its at-the-market offering program since the current fiscal quarter began on July 1, 2025. A registered direct offering places registered shares straight with chosen investors. An at-the-market program sells shares into the market over time.
The 8-K does not split the total between the two parts. It gives no share count and no price per share for either.
No warrants or repricing features
NRx says that the August offering and the at-the-market sales each include no warrants, repricing adjustments or other variable-rate features. The filing says such features can change the price at which investors receive shares later.
The company also says a substantial majority of the $8.8 million in gross proceeds from the sale of common stock was placed with experienced biotech investors. The 8-K does not name those investors or say how much each took.
NRx will return to reporting its at-the-market proceeds in its quarterly reports on Form 10-Q. The 8-K and the September 2 press release are furnished rather than filed, which the company says keeps them outside Section 18 of the Securities Exchange Act of 1934.
Banks and advisors
The 8-K names no underwriter, placement agent, sales agent for the at-the-market program, lender or legal counsel for either the August offering or the at-the-market sales. The business section of the annual report for 2024, filed March 14, 2025, names none of them either.
The financing history
The annual report describes earlier financing with an institutional investor for up to $16.3 million in debt capital. The company closed $10.87 million of that in 2024. It then closed $8.5 million in January 2025 in a combination of convertible debt and an above-market common stock and warrant offering. The January deal therefore included warrants, while the company says the September clarification concerns sales with none.
When the annual report was filed, management was negotiating a term sheet with a publicly traded strategic investor and was talking with commercial lenders about financing clinic acquisitions. The annual report said management believed those financings would give the company enough money to complete its acquisitions and business plan, if they closed. The 8-K does not say whether the strategic investor or any lender took part in the 2025 sales.
The annual report ties those clinic acquisitions to a plan to move NRx from a pre-revenue biotechnology company to a revenue-generating enterprise. That plan runs through HOPE Therapeutics, Inc., a medical care delivery organization NRx incorporated in February 2024 to operate interventional psychiatric clinics.
What the filing leaves out
The 8-K gives no cash balance, net loss or share count after the sales, so the new proceeds cannot be measured against the company's burn from these documents. The company describes the clarification as ministerial, and the filing corrects only the composition of the $8.8 million figure.